The Study of Structural and Functional Brain Abnormalities and the Association With the Genetic Polymorphism in the Type 2 Diabetes Patient With Depression
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- the neuroimaging of Type 2 Diabetes and Depression
Study Overview
Brief Summary
To investigate the structural/functional abnormalities and the possible genetic endophenotypes of in the Type 2 Diabetes Patient With Depression.
Detailed Description
Diabetes and depression are harmful to human health,but they often co-exist.At present, the pathophysiological mechanisms underlying the comorbidity of diabetes and depression are discussed, including hypothalamic-pituitary-adrenal axis dysfunction, inflammation, epigenetics, disturbed circadian rhythms, environmental and behavioral factors,neuroimaging,etc.the purpose of the investigator's study is to investigate the structural/functional abnormalities and the possible genetic endophenotypes of in the Type 2 Diabetes Patient With Depression.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 30 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •conform to type 2 diabetes, depression, diagnostic criteria of unrelated normal controls the han nationality patients; Aged 30 to 70 years of age, gender not limited; The patient or legal guardian have signed informed consent of patients.
Exclusion Criteria
- •Magnetic resonance imaging has the contraindication, such as metal implants, claustrophobic, etc.
- •With severe body diseases, including inflammatory diseases and autoimmune diseases; Current or past history of nervous system disease or brain injury. Merge other severe mental illness or existing psychotic symptoms; Always have a mania, hypomania attack; Has a history of substance abuse; Pregnant women and nursing mothers; Estimated compliance is poorer, not partners; Is being treated for a mental drug therapy, and ECT, TMS; Patients with a body mass index > 35; There are currently no taking corticosteroids, immune regulator, etc. Now or ever did not suffer from patients with other diagnosis to the dsm-iv axis I; Merge the endocrine system disease, thyroid, adrenal gland and pituitary gland diseases, etc.
Outcomes
Primary Outcomes
the neuroimaging of Type 2 Diabetes and Depression
Time Frame: from 2017-12 to 2019-12
the structure and function of Abnormalities in the T2DM Patients
Secondary Outcomes
No secondary outcomes reported
Investigators
Yuqi Cheng
associate professor
Kunming Medical University